Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration

Survey of Ophthalmology

Volumn 45, Issue 3, 2000, Pages 195-214

  Schmidt Erfurth, Ursula ^a   Hasan, Tayyaba ^b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CIBA Vision Corporation   (United States)

Author keywords

Age related macular degeneration; Benzoporphyrin derivative; Mechanisms of action; Photodynamic therapy; Verteporfin

Indexed keywords

ASPARTIC ACID; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; CHLOROALUMINUM PHTHALOCYANINE; ETIOPURPURIN; FLUORESCEIN; HEMATOPORPHYRIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; ROSE BENGAL;

ARTICLE; BLINDNESS; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEUROEPITHELIAL LAYER; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANIMALS; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROGNOSIS; VISUAL ACUITY;

EID: 0033694993     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(00)00158-2     Document Type: Article

References (97)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP Study group)
2. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
3. Argon green vs krypton red laser photocoagulation of extrafoveal choroidal neovascular lesions. One-year results in age-related macular degeneration
4. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
5. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration
6. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative
7. Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin
8. Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration
9. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA)
10. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA)
11. Science, medicine, and the future. New techniques in laser therapy
12. Structure and biodistribution relationships of photodynamic sensitizers
13. Age-related macular degeneration
14. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration
15. Hydrogen peroxide and hydroxyl free radical production by hematoporphyrin derivative, ascorbate and light
16. Photodynamic therapy
17. Age-related macular degeneration and blindness due to neovascular maculopathy
18. Vascular effects of photodynamic therapy
19. Lipoprotein receptors and endothelial cells
20. Age-related macular degeneration and choroidal neovascularization
21. Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells
22. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy
23. Photodynamic therapy in the treatment of malignancies
24. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization
25. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye
26. Photodynamic therapy of cancer
27. The synthesis, photophysical and photobiological properties and in vitro structure-activity relationships of a set of silicon phthalocyanine PDT photosensitizers
28. Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction
29. How does photodynamic therapy work?
30. Hematoporphyrin derivative-induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230AC mammary adenocarcinomas of rats
31. Immunological aspects of photodynamic therapy
32. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization
33. Long-term effect of photodynamic therapy (PDT) using liposomal benzoporphyrin derivative (BPD) on experimental choroidal neovascularization (CNV) and normal retina and choroid
34. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells
35. Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy
36. The role of lipoproteins in the delivery of tumour-targeting photosensitizers
37. Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients
38. Sites of photosensitization by derivatives of hematoporphyrin
39. Phthalocyanine photodynamic therapy: New strategy for closure of choroidal neovascularization
40. Angiography and photodynamic therapy of experimental choroidal neovascularization using phthalocyanin dye
41. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative mono-acid (BPD-MA) angiography
42. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys
43. Photodynamic therapy
44. The clinical status of benzoporphyrin derivative
45. The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative
46. Photodynamic therapy of malignant skin tumors with BPD-MA
47. Photodynamic therapy of subretinal neovascularization in the monkey eye
48. Photodynamic therapy of subretinal neovascularization in the monkey eye
49. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study
50. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin
51. Photodynamic therapy (PDT) with verteporfin of subfoveal choroidal neovascularization in age-related macular degeneration: Study design and baseline characteristics in the VIP randomized clinical trial
52. Photodynamic therapy for choroidal neovascularization with a hydrophilic sensitizer: NPe6
53. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6)
54. Photodynamic occlusion of retinal vessels using tin ethyl etiopurpurin (SnET2). An efficacy study
55. Laser targeted photodynamic therapy occludes experimental choroidal neovascularization without visible damage to RPE and choriocapillaris
56. Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors
57. Photodynamic occlusion of the choroidal neovascularization of primate eyes using a new hydrophilic photosensitizer, ATX-S10
58. Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10
59. Prolonged skin allograft survival after photodynamic therapy associated with modification of donor skin antigenicity
60. Photophysical and photobiological processes in the photodynamic therapy of tumours
61. Light history and age-related changes in retinal light damage
62. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2)
63. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey
64. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice
65. Preliminary studies on a more effective phototoxic agent than hematoporphyrin
66. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model
67. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model
68. Mouse skin photosensitization with benzoporphyrin derivatives and Photofrin: Macroscopic and microscopic evaluation
69. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents
70. On the problems involved in detecting luminescence from singlet oxygen in biological specimens
71. Photodynamic therapy begins to shine
72. Indocyanine green angiography and retinal sensitivity after photodynamic therapy of subfoveal choroidal neovascularization
73. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin
74. Photodynamic therapy in ocular vascular disease
75. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates
76. Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors
77. Photodynamic therapy of experimental, intraocular tumors with benzoporphyrin-lipoprotein
78. Vascular targeting in photodynamic occlusion of subretinal vessels
79. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization
80. ICG-angiographic analysis of the photodynamic mechanism in treatment of choroidal neovascularization
81. Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples
82. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study
83. Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results
84. Photodynamic therapy of human ocular cancer
85. Photoinactivation of amelanotic and melanotic melanoma cells sensitized by axially substituted Si-naphthalocyanines
86. Depolarization of mouse myeloma cell membranes during photodynamic action
87. On the physical rationale of photodynamic therapy
88. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative
89. Closure of experimental subretinal neovascular vessels with dihematoporphyrin ether augmented argon green laser photocoagulation
90. Visual acuity stabilizes after a single treatment with Snet2-photodynamic therapy in patients with subfoveal choroidal neovascularization
91. Purlytin (SnET2)-photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans
92. Experimental photocoagulation of the human retina. I. Correlation of physical, clinical, and pathologic data
93. Light sources for photodynamic therapy
94. Photodynamic therapy: Light delivery and dosage for second-generation photosensitizers
95. Phototherapy of cancer and atheromatous plaque with texaphyrins
96. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer